Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2009 Oct;64(10):1472-1477.
doi: 10.1111/j.1398-9995.2009.02051.x. Epub 2009 Apr 14.

The size of the disease relevant IgE antibody fraction in relation to 'total-IgE' predicts the efficacy of anti-IgE (Xolair) treatment

S G O Johansson  1   2 , A Nopp  1 , H Öman  3 , J Ankerst  4 , L O Cardell  5 , R Grönneberg  6 , H Matsols  7 , S Rudblad  8 , V Strand  9 , G Stålenheim  10
Affiliations
Randomized Controlled Trial

The size of the disease relevant IgE antibody fraction in relation to 'total-IgE' predicts the efficacy of anti-IgE (Xolair) treatment

S G O Johansson et al. Allergy. 2009 Oct.

Abstract

Background: Some patients with allergic asthma treated with anti-IgE (Xolair) do not become symptom free. Better criteria for response assessment than allergy skin tests or IgE determination are needed. The impact of the size of the disease relevant allergen-specific IgE antibody fraction, i.e. the percentage of IgE antibody of total IgE, was evaluated in cat allergic patients treated with the recommended doses of Xolair. Results were measured as changes in basophil allergen threshold sensitivity (CD-sens).

Methods: In a double-blind placebo controlled trial 20 patients with a high (>3.8%) and 18 with a low (<1%) percentage of IgE antibodies to cat were given Xolair for 16 weeks and the change in CD-sens was compared to 11 and 10 patients, respectively, in each group receiving placebo.

Results: The CD-sens dropped significantly in both the high (P < 0.001) and low (P < 0.001) group on Xolair but did not change significantly after placebo. For Xolair-treated patients, at the end of the trial there was a highly significant (P < 0.001) difference in CD-sens between the high group, where no patients, and the low group, where 13/18 patients, had become negative.

Conclusions: The currently recommended doses of Xolair very efficiently eliminate IgE antibodies if the IgE antibody fraction is <1% of total IgE but has not enough effect on allergen sensitivity if the fraction is >3-4%. Further studies will show if increased doses of Xolair would help also these patients, who seem to represent about 1/3 of the patient population.

PubMed Disclaimer

References

    1. Holgate ST, Chuchalin AG, Hebert J, Lotvall J, Persson BG, Chung KF et al. Efficacy and safety of a recombinant anti-IgE antibody (omalizumab) in severe allergic asthma. Clin Exp Allergy 2004;34:632-638.
    1. Xolair (omalizumab), Summary of Product Characteristics: http://www.emea.eu.int/humandocs/PDFs/EPAR/Xolair/H-606-PI-en-pdf .
    1. Nopp A, Johansson SGO, Ankerst J, Bylin G, Cardell LO, Grönneberg R et al. Basophil allergen threshold sensitivity. A useful approach to anti-IgE treatment efficacy evaluation. Allergy 2006;61:298-302.
    1. Holgate ST. Implications for clinical practice, in anti-IgE therapy. A new area in the control of severe persistent allergic asthma? European Respiratory Society Congress, Copenhagen, 19 September, 2005.
    1. Johansson SGO, Öman H, Nopp A, Pettersson S. The importance of IgE antibody levels in anti-IgE treatment. Allergy 2006;61:1216-1219.

Publication types

MeSH terms

LinkOut - more resources